Corneal erosion is a common ocular condition that can cause significant pain and discomfort. It is characterized by a loss of the protective outer layer of the cornea, which can lead to sensitivity to light, blurred vision, and foreign body sensation. Recurrent corneal erosion (RCE) is a particularly problematic form of the condition in which the erosion occurs repeatedly. It is estimated that RCE affects between 0.2% and 4.3% of the population, and is more common in people with certain risk factors such as contact lens use, dry eye, and previous ocular surgery. The management of RCE is challenging due to its recurrent nature. Conventional treatments such as the use of topical antibiotics and topical steroids are often ineffective, and the condition can be difficult to control. In recent years, there have been a number of advances in the prevention and treatment of RCE, including the use of newer medications, surgical techniques, and lifestyle modifications. This article will discuss these new strategies for tackling recurrent corneal erosion.
Topical medications are commonly used to treat RCE, and there are a number of newer medications that have been developed in recent years. One of the most commonly used medications is the antibiotic moxifloxacin, which has been shown to reduce the frequency of recurrences. Other antibiotics such as ofloxacin, gatifloxacin, and levofloxacin have also been used with some success. In addition to antibiotics, other medications such as cyclosporine, tacrolimus, and corticosteroids have been used to reduce the inflammation associated with RCE. These medications can be used alone or in combination with antibiotics.
In some cases, surgical techniques may be used to treat RCE. These techniques include phototherapeutic keratectomy (PTK) and debridement. PTK is a procedure in which the affected corneal tissue is removed using a laser. This can reduce the frequency of recurrences and improve symptoms. Debridement is a procedure in which the affected corneal tissue is scraped away using a scalpel. This can help to remove any debris or bacteria that may be causing the erosion.
Lifestyle modifications can also be beneficial in the management of RCE. These include avoiding contact lenses, using artificial tears, and wearing protective eyewear. Contact lenses should be avoided in people with RCE, as they can increase the risk of recurrences. Artificial tears can help to reduce the symptoms associated with RCE, and protective eyewear can help to protect the eyes from further damage.
Recurrent corneal erosion is a challenging condition to manage due to its recurrent nature. There have been a number of advances in the prevention and treatment of RCE in recent years, including the use of newer medications, surgical techniques, and lifestyle modifications. These strategies can help to reduce the frequency of recurrences and improve symptoms. It is important to discuss any treatment options with an ophthalmologist to determine the best course of action.
1.
What is Mohs micrographic surgery? 8 FAQs about Mohs
2.
The Higher the Disability Burden From Disease, the Higher the Suicide Risk
3.
Older Men Increasingly Overtreated for Prostate Cancer, Study Suggests
4.
Anticoagulation for 12 months has been found to improve outcomes in cancer patients with minor blood clots.
5.
Addition of regional nodal irradiation does not decrease rates of invasive breast cancer recurrence, study finds
1.
Biomimetic Nanovesicles for Breast Cancer: Targeting Senescence to Overcome Chemoresistance
2.
Essential Oncology Updates: Diagnosis, Treatment Advances, Tools & Education Resources
3.
Enhancing Cancer Care: From Diagnosis Through Survivorship and Beyond
4.
Omentum Cancer: Causes, Symptoms, and Treatment Options
5.
Acrochordon: What It Is, Causes, And How To Manage This Skin Condition
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part IV
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I
4.
The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part II
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation